This company has been marked as potentially delisted and may not be actively trading. NASDAQ:YMTX Yumanity Therapeutics (YMTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Yumanity Therapeutics Stock (NASDAQ:YMTX) Get Yumanity Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.56▼$1.8952-Week Range N/AVolume6,790 shsAverage Volume473,083 shsMarket Capitalization$7.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Read More Receive YMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. YMTX Stock News HeadlinesJSPR Jasper Therapeutics, Inc.March 20, 2024 | seekingalpha.comCara Therapeutics Inc CARANovember 3, 2023 | morningstar.comMBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.October 23 at 2:00 AM | Banyan Hill Publishing (Ad)Yumanity Therapeutics Inc.October 6, 2023 | thestreet.comFormer Onyx CEO Returns to Biotech to Launch Boston Start UpJuly 5, 2023 | thestreet.comKineta raises $6M through registered direct offeringMay 1, 2023 | bizjournals.comColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus ReportsFebruary 22, 2023 | finance.yahoo.comYumanity Therapeutics's Return On Capital Employed InsightsDecember 26, 2022 | msn.comSee More Headlines YMTX Stock Analysis - Frequently Asked Questions How were Yumanity Therapeutics' earnings last quarter? Yumanity Therapeutics, Inc. (NASDAQ:YMTX) posted its earnings results on Thursday, August, 12th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The business earned $2.11 million during the quarter, compared to the consensus estimate of $2.27 million. Yumanity Therapeutics had a negative trailing twelve-month return on equity of 263.34% and a negative net margin of 660.61%. What other stocks do shareholders of Yumanity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Yumanity Therapeutics investors own include NIO (NIO), Arch Therapeutics (ARTH), Aytu BioPharma (AYTU), Clarus Therapeutics (CRXTQ), Ford Motor (F), Novavax (NVAX) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/12/2021Today10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:YMTX CIK1445283 Webwww.yumanity.com Phone(617) 409-5300FaxN/AEmployees40Year Founded2014Profitability EPS (Trailing Twelve Months)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.50 million Net Margins-660.61% Pretax Margin-660.61% Return on Equity-263.34% Return on Assets-107.08% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio2.21 Sales & Book Value Annual Sales$4.84 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / BookN/AMiscellaneous Outstanding Shares10,856,000Free Float9,504,000Market Cap$7.46 million OptionableNot Optionable Beta0.32 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:YMTX) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yumanity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Yumanity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
